This study is in progress, not accepting new patients
Long Term Extension Study in Patients With Primary Hyperoxaluria
Summary
- Location
- at UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Marshall Stoller (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Marshall Stoller (ucsf)
My clinical and research efforts continue to be centered around the treatment and understanding the pathogenesis of urinary stone disease. I have recently identified zinc as a critical factor in the early mineralization process.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- ID
- NCT04042402
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 75 study participants
- Last Updated